Azenta, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Martin D. Madaus
- Full Time Employees
- 2,900
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 200 Summit Drive Burlington MA United States of America 01803
- IPO Date
- Feb 2, 1995
- CIK
- 0000933974
- Website
- azenta.com
- Similar Companies
- Business
- Azenta, Inc. Azenta, Inc. (Nasdaq: AZTA) provides life sciences sample exploration and management solutions to pharmaceutical, biotechnology, academic, and healthcare institutions worldwide. The company offers consumables and instruments including 2D sample storage tubes and bench-top equipment from brands such as FluidX, Ziath, and 4titude; automated stores and cryogenics systems; sample storage and repository services through BioStorage Technologies; GENEWIZ multiomics and synthesis solutions encompassing next-generation sequencing, genomics, and transgene expression cassettes; sample management LIMS software like FreezerPro and Limfinity; cold chain solutions from B Medical Systems including temperature-controlled storage and transportation; and biological sample preparation from Matrical Bioscience. Azenta operates globally across North America, Europe, and Asia from its headquarters in Burlington, Massachusetts, where it was rebranded from Brooks Automation in December 2021 following a corporate restructuring that divested its semiconductor solutions group. Recent developments include a May 2025 strategic partnership with Form Bio to integrate GENEWIZ sequencing with AI-driven AAV gene therapy analysis for improved vector safety and development speed; and a November 2025 collaboration with the PRECEDE Foundation to provide biorepository storage and logistics for pancreatic cancer early detection research.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
Analysts Set Azenta, Inc. (NASDAQ:AZTA) PT at $41.20
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
Jupiter Topco LLC Takes Position in Azenta, Inc. $AZTA
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
7,529,450 Shares in Azenta, Inc. $AZTA Acquired by BlackRock Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
American Capital Management Inc. Buys Shares of 1,061,490 Azenta, Inc. $AZTA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
AZENTA ANNOUNCES LEADERSHIP TRANSITION
Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue
Azenta, Inc. $AZTA Shares Sold by Bank of New York Mellon Corp
Arrowstreet Capital Limited Partnership Buys New Position in Azenta, Inc. $AZTA
Azenta, Inc. (AZTA) Q3 2026 Earnings Call Transcript
Azenta Q3 Earnings Call Highlights